European Medicines Agency Committee Backs Roche's Subcutaneous Injection for Multiple Sclerosis

Roche (RO.SW, ROG.SW) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of Ocrevus subcutaneous injection for multiple sclerosis

MT Newswires13:24

J&J, Roche, AstraZeneca Poised to Have Highest Orphan Drug Sales by End of Decade

Seeking Alpha01:00

Express News | According to the Ministry of Commerce's website, on April 26, Deputy Director Wang Yupeng met with Xu Jian, head of the China Corporate Affairs and Market Access Department of Roche Diagnostics. The two sides exchanged views on Roche's cooperation with Ch

BreakingsApr 26 17:13

Phase 3 clinical trial of Roche (RHHBY.US) major antibody therapy Ocrevus obtained positive data

Recently, Genentech (Genentech), a subsidiary of Roche (RHHBY.US), announced that its major antibody therapy Ocrevus obtained positive data in the phase 3 clinical study Ocarina II for the treatment of recurrent or primary progressive multiple sclerosis (RMS or PPMS). The results showed that the Ocrevus subcutaneous preparation, which only took two doses a year, almost completely suppressed clinical recurrence and brain lesions.

Zhitong FinanceApr 26 11:33

Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5%

Chugai Pharmaceutical's (TYO:4519) parent company, Roche Holding, posted group sales of 14.4 billion Swiss francs for the first quarter, down 6% from 15.3 billion francs a year earlier, according to a

MT NewswiresApr 25 13:17

DZ BANK AG Sticks to Its Buy Rating for Roche Holding AG (RHHVF)

TipRanksApr 25 00:25